Viewing Study NCT01640951

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs
Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug
Ignite Creation Date: 2025-12-24 @ 11:53 PM
Ignite Modification Date: 2026-05-18 @ 8:19 PM
Study NCT ID: NCT01640951
Status: COMPLETED
Last Update Posted: 2018-05-25
First Post: 2012-07-12
Is NOT Gene Therapy: True
Has Adverse Events: True
Brief Title: 4 Year Extension Study of Efficacy and Safety of Secukinumab in Patients With Moderate to Severe Chronic Plaque-type Psoriasis
Sponsor: Novartis Pharmaceuticals
Organization:
Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Moderate to Severe Chronic Plaque-Type Psoriasis View
Keywords:

Keywords

Keyword Brief Keyword Text View
None Psoriasis View
None Plaque View
None Inflammatory skin disease View
None Scaly patches View
None AIN457 View
None Secukinumab View
None Moderate to Severe Plaque-type Psoriasis View